News and Comments

The FDA Approval Of Kynamro™ Promises ISIS A Bright Future Read Also about ALNY; Sarepta, SNY

  Thursday, January 31, 2013


Illumina, Roche and Fairness

  Thursday, February 09, 2012

Illumina (ILMN) is occupying the center stage these days. Roche’s persistent attempts to acquire ILMN, has opened investors’ eyes on the importance of this firm’s technology in moving away from the road of stagnation to that of innovation. Innovation is the insurance that guarantees the survival and growth of the drug companies in the future that has already begun. Illumina’s technologies and marketed state-of-the-art sequencers and gene analyzers have been a major contributor to the flourishing of information about the origins of diseases at the molecular level.  This capability, which lured Roche, was overlooked by Wall Street investors who have recently caused a selloff in the stock for theorized reasons. The real value of Illumina resides in its indispensability as the cornerstone of future advancement in medical diagnosis and treatment. With all the new-targeted drugs on the market and in the firms’ pipelines, the current diagnostic and treatment statuses are still far from perfect. More...

Monster Blockbuster Anti-Cholesterol Drugs In Biotechs’ Pipelines

  Wednesday, August 31, 2011

The new biological science is evolving at the speed of light. As a matter of fact, the bright penetrating light of the genomic revolution is effectively reaching the dark corners where the utmost reality remained hidden since millions of years. The new light enabled the insight to match the sight in divulging the buried secrets of body at the molecular level. With the most advanced tools ever created by human minds, scientists have reached a stage where they can spend much less effort in solving much more puzzles on the road towards solving the problems of diseases at their root-origin. The successful are those researchers who keep their eyes open and their minds prepared. More...

Recent Postings



Telaprevir Seattle Genetics (SGEN) Genentech CompuGen (CGEN) Agenus (AGEN) TOKAI (TKAOI) Auspex (ASPX) IDERA (IDRA) Idenix (IDIX) Illumina (ILMN) Incyte (INCY) Jazz Pharmaceuticals (JAZZ) OSI (OSIP) ISIS (ISIS) Dendreon (DNDN) Ariad (ARIA) Alnylam (ALNY) Intrexon (XON) NEKTAR (NKTR)) ARCA (ABIO) Array Pharmaceuticals (ARRY) Mirati Therapeutics (MRTX) Agenus (AGEN KITE (KITE) Prolor Biotech (PBTH) Anacor (ANAC) Inovio (INO) Anadys (ANDS) Sanofi (SNA) Multiple Myeloma Rapamune JUNO (JUNO) Human Genome Sciences (HGSI) Ridaforolimus NANTKWEST (NK) ZALTRAP™ Sangamo (SGMO) Biocryst (BCRX) Roche (ROCHE) Aimmune Therapeutics (AIMT) Biogen Idec (BIIB) Intercept (ICPT) Sarepta (SRPT) ImmunoGen (IMGN) Valeant Pharmaceuticals International (VRX) C4 Therapeutics Prosensa (RNA) Cytokinetics (CYTK) AERIE PHARMACEUTICALS BIOMARIN (BMRN) VANDA (VNDA) Tysabri Sanofi (SNY) Micromet (MITI) ABBVIE (ABBV) Xoma (XOMA) Elan (ELN) Zerenex Intermune (ITMN) Bristol-Myers Squibb (BMY) Abbott Laboratories (ABT) Pluristem (PSTI) SYNTA (SNTA) Endometrial Cancer GlaxoSmithKline (GSK) Revlimid (lenolidamide) Ziofpharm (ZIOP) Benlysta (belimumab) Vertex (VRTX) Amgen (AMGN) Regeneron (REGN) KERYX (KERX) Exelixis (EXEL) Sequenom (SQNM) Sanofi-Aventis (SAN) Trastuzumab-DM1 Theravance (THRX) SUNESIS PHARMACEUTICALS (SNSS) ADVENTRIX (ANX) Roche (RHHBY) SERES THERAPEUTICS (MCRB) Gilead (GILD) Velcade (bortezomib) Merck (MRK) Dynavax (DVAX) HALOZYME (HALO) Galena (GALE) GUARDIAN HEALTH Onyx (ONXX) Herceptin galapagos (GLPG)